Zalicus, formerly CombinatoRx, discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases. The company applies its selective ion-channel modulation platform and its combination high throughput screening capabilities to discover innovative therapeutics for both internal product pipeline and its collaborators.

In 2005, Zalicus raised a $42M IPO. In 2014, Zalicus merged with Epirus Biopharmaceuticals, a Boston-based company focused on biosimilars.


Company Profile

Zalicus Logo
  • Founded: 2002

Flagship Partners:

  • Doug Cole, Managing Partner